No Data
H.C. Wainwright Maintains Imunon(IMNN.US) With Buy Rating, Cuts Target Price to $25
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)
Express News | IMUNON Eliminates Headcount Not Essential To Phase 3 Trial
IMUNON, Inc. Announces Strategic Restructuring and Retirement of Chief Scientific Officer to Advance Phase 3 Clinical Trial
Express News | Imunon Inc - Khursheed Anwer to Retire as Evp and Cso
Express News | Imunon Inc: Phase 3 Study Enrollment Remains Ahead of Schedule and Advances Company Toward Future Bla Filing